FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923675504> ?p ?o ?g. }

• W2923675504 endingPage "1707" @default.
• W2923675504 startingPage "1699" @default.
• W2923675504 abstract "The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been expressed. This study investigated whether CT-P13 is non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy.In this randomised, multicentre, double-blind, phase 3 non-inferiority study, we enrolled patients with active Crohn's disease who had not responded to, or were intolerant to, non-biological treatments. Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. Patients received 5 mg/kg CT-P13 or infliximab at weeks 0, 2, 6, and then every 8 weeks up to week 54. The primary endpoint was the proportion of patients with a decrease of 70 points or more in Crohn's Disease Activity Index (CDAI) from baseline to week 6. A non-inferiority margin of -20% was set (CT-P13 was non-inferior to infliximab if the lower limit of the two-sided 95% CI for the treatment difference was greater than -20). This trial is registered with ClinicalTrials.gov, number NCT02096861, and is completed.Between Aug 20, 2014, and Feb 15, 2017, 308 patients were assessed for eligibility, and 220 patients were enrolled: 111 were randomly assigned to initiate CT-P13 (56 to the CT-P13-CT-P13 group and 55 to the CT-P13-infliximab group) and 109 to initiate infliximab (54 to the infliximab-infliximab group and 55 to the infliximab-CT-P13 group). CDAI-70 response rates at week 6 were similar for CT-P13 (77 [69·4%, 95% CI 59·9 to 77·8] of 111) and infliximab (81 [74·3%, 95% CI 65·1 to 82·2] of 109; difference -4·9% [95% CI -16·9 to 7·3]), thereby establishing non-inferiority. Over the total study period, 147 (67%) patients experienced at least one treatment-emergent adverse event (36 [64%] in the CT-P13-CT-P13 group, 34 [62%] in the CT-P13-infliximab group, 37 [69%] in the infliximab-infliximab group, and 40 [73%] in the infliximab-CT-P13 group).This study showed non-inferiority of CT-P13 to infliximab in patients with active Crohn's disease. Biosimilar CT-P13 could be a new option for the treatment of active Crohn's disease.Celltrion, Pfizer." @default.
• W2923675504 created "2019-04-01" @default.
• W2923675504 creator A5006742544 @default.
• W2923675504 creator A5008706459 @default.
• W2923675504 creator A5010089498 @default.
• W2923675504 creator A5011861620 @default.
• W2923675504 creator A5022998619 @default.
• W2923675504 creator A5030471414 @default.
• W2923675504 creator A5032304413 @default.
• W2923675504 creator A5042578178 @default.
• W2923675504 creator A5042767369 @default.
• W2923675504 creator A5043460497 @default.
• W2923675504 creator A5046923052 @default.
• W2923675504 creator A5059435501 @default.
• W2923675504 creator A5059865111 @default.
• W2923675504 creator A5064256349 @default.
• W2923675504 creator A5066248911 @default.
• W2923675504 creator A5066408904 @default.
• W2923675504 creator A5074950867 @default.
• W2923675504 creator A5076575654 @default.
• W2923675504 creator A5085146978 @default.
• W2923675504 creator A5089661109 @default.
• W2923675504 date "2019-04-01" @default.
• W2923675504 modified "2023-10-16" @default.
• W2923675504 title "Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study" @default.
• W2923675504 cites W1251997985 @default.
• W2923675504 cites W1965347749 @default.
• W2923675504 cites W1980282196 @default.
• W2923675504 cites W1993862222 @default.
• W2923675504 cites W2052496052 @default.
• W2923675504 cites W2071662837 @default.
• W2923675504 cites W2112635226 @default.
• W2923675504 cites W2115865518 @default.
• W2923675504 cites W2121050884 @default.
• W2923675504 cites W2126807394 @default.
• W2923675504 cites W2158713672 @default.
• W2923675504 cites W2161723853 @default.
• W2923675504 cites W2162768160 @default.
• W2923675504 cites W2171341132 @default.
• W2923675504 cites W2321453230 @default.
• W2923675504 cites W2515296740 @default.
• W2923675504 cites W2523706394 @default.
• W2923675504 cites W2583464358 @default.
• W2923675504 cites W2613299853 @default.
• W2923675504 cites W2733544055 @default.
• W2923675504 cites W2751387666 @default.
• W2923675504 cites W2755110485 @default.
• W2923675504 cites W2765309378 @default.
• W2923675504 cites W2795103548 @default.
• W2923675504 cites W3149527659 @default.
• W2923675504 doi "https://doi.org/10.1016/s0140-6736(18)32196-2" @default.
• W2923675504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30929895" @default.
• W2923675504 hasPublicationYear "2019" @default.
• W2923675504 type Work @default.
• W2923675504 sameAs 2923675504 @default.
• W2923675504 citedByCount "142" @default.
• W2923675504 countsByYear W29236755042019 @default.
• W2923675504 countsByYear W29236755042020 @default.
• W2923675504 countsByYear W29236755042021 @default.
• W2923675504 countsByYear W29236755042022 @default.
• W2923675504 countsByYear W29236755042023 @default.
• W2923675504 crossrefType "journal-article" @default.
• W2923675504 hasAuthorship W2923675504A5006742544 @default.
• W2923675504 hasAuthorship W2923675504A5008706459 @default.
• W2923675504 hasAuthorship W2923675504A5010089498 @default.
• W2923675504 hasAuthorship W2923675504A5011861620 @default.
• W2923675504 hasAuthorship W2923675504A5022998619 @default.
• W2923675504 hasAuthorship W2923675504A5030471414 @default.
• W2923675504 hasAuthorship W2923675504A5032304413 @default.
• W2923675504 hasAuthorship W2923675504A5042578178 @default.
• W2923675504 hasAuthorship W2923675504A5042767369 @default.
• W2923675504 hasAuthorship W2923675504A5043460497 @default.
• W2923675504 hasAuthorship W2923675504A5046923052 @default.
• W2923675504 hasAuthorship W2923675504A5059435501 @default.
• W2923675504 hasAuthorship W2923675504A5059865111 @default.
• W2923675504 hasAuthorship W2923675504A5064256349 @default.
• W2923675504 hasAuthorship W2923675504A5066248911 @default.
• W2923675504 hasAuthorship W2923675504A5066408904 @default.
• W2923675504 hasAuthorship W2923675504A5074950867 @default.
• W2923675504 hasAuthorship W2923675504A5076575654 @default.
• W2923675504 hasAuthorship W2923675504A5085146978 @default.
• W2923675504 hasAuthorship W2923675504A5089661109 @default.
• W2923675504 hasConcept C126322002 @default.
• W2923675504 hasConcept C141071460 @default.
• W2923675504 hasConcept C168563851 @default.
• W2923675504 hasConcept C203092338 @default.
• W2923675504 hasConcept C2777138892 @default.
• W2923675504 hasConcept C2777402515 @default.
• W2923675504 hasConcept C2777575956 @default.
• W2923675504 hasConcept C2779134260 @default.
• W2923675504 hasConcept C2779280984 @default.
• W2923675504 hasConcept C59491497 @default.
• W2923675504 hasConcept C71924100 @default.
• W2923675504 hasConcept C90924648 @default.
• W2923675504 hasConceptScore W2923675504C126322002 @default.
• W2923675504 hasConceptScore W2923675504C141071460 @default.
• W2923675504 hasConceptScore W2923675504C168563851 @default.
• W2923675504 hasConceptScore W2923675504C203092338 @default.

• next